Is Empagliflozin Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Empagliflozin? Is Empagliflozin safe for nursing mother and child? Does Empagliflozin extracts into breast milk? Does Empagliflozin has any long term or short term side effects on infants? Can Empagliflozin influence milk supply or can Empagliflozin decrease milk supply in lactating mothers?

• DrLact safety Score for Empagliflozin is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of Empagliflozin may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that Empagliflozin may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using Empagliflozin .
• It is recommended to evaluate the advantage of not breastfeeding while using Empagliflozin Vs not using Empagliflozin And continue breastfeeding.
• While using Empagliflozin Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Dapagliflozin is a selective and reversible inhibitor of the sodium and glucose co-transporter 2 (SGLT2). It acts by reducing the renal reabsorption of glucose and increasing its elimination via urine (Kasichayanula 2014, Plosker 2014).Administered orally once a day. Low risk of hypoglycemia in monotherapy, which increases when it is associated with other hypoglycaemic agents (EMA 2017, Plosker 2014). Since the last update, we have not found published data on its excretion in breast milk. Its high percentage of protein binding (EMA 2017) makes its transfer to milk in significant quantities unlikely, but the low molecular weight and its elimination half-life greater than 12 hours could facilitate a possible transfer. Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity. Diet, exercise and breastfeeding improve blood glucose levels.

No information is available on the clinical use of empagliflozin during breastfeeding. Empagliflozin is an uncharged molecule that is 86% protein bound in plasma, so it is unlikely to pass into breastmilk in clinically important amounts. The manufacturer does not recommend empagliflozin during breastfeeding because of a theoretical risk to the infant's developing kidney. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.